Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | HTR1D | P28221 | 2/20 | 0.49 |
| ▸ | HTR1B | P28222 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373916 | 0.93 | KMT2A (0.60) | KMT2AMEN1RAB9ADRD2DRD3 | |
| SCHEMBL3373703 | 0.90 | KMT2A (0.67) | KMT2AMEN1RAB9ADRD2DRD3 | |
| SCHEMBL3375958 | 0.86 | GRIN2B (0.60) | KMT2AMEN1RAB9AALDH1A1SLC6A2 | |
| SCHEMBL3373138 | 0.85 | SLC6A2 (0.51) | KMT2AMEN1RAB9AALDH1A1SLC6A2 | |
| SCHEMBL9455273 | 0.84 | GRIN2B (0.58) | KMT2AMEN1RAB9AALDH1A1SLC6A2 | |
| SCHEMBL28410816 | 0.83 | G6PC1 (0.54) | KMT2AMEN1RAB9AALDH1A1SLC6A2 | |
| SCHEMBL515999 | 0.83 | G6PC1 (0.54) | KMT2AMEN1RAB9AALDH1A1SLC6A2 | |
| SCHEMBL7885548 | 0.83 | G6PC1 (0.54) | KMT2AMEN1RAB9AALDH1A1SLC6A2 | |
| SCHEMBL18828594 | 0.83 | LTA4H (0.60) | KMT2AMEN1RAB9AALDH1A1SLC6A2 | |
| SCHEMBL13017781 | 0.83 | SLC6A2 (0.53) | KMT2AMEN1RAB9AALDH1A1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | KMT2A 4670/4885MEN1 2985/4885RAB9A 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.